Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.77% | -31.22% | -8.84% | 7.68% | 16.73% |
| Total Depreciation and Amortization | 9.42% | 21.37% | 43.44% | 31.42% | 16.64% |
| Total Amortization of Deferred Charges | -6.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -45.38% | 98.99% | 728.14% | 310.54% | 119.30% |
| Change in Net Operating Assets | -113.80% | 148.46% | -2,233.62% | 247.74% | -57.85% |
| Cash from Operations | -65.79% | 50.27% | 30.21% | 46.25% | 43.17% |
| Capital Expenditure | 95.85% | 31.67% | -12.01% | 81.67% | 83.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 146.64% | 129.50% | -12.01% | 81.67% | 83.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.91% | -41.53% | 28.35% | 121.90% | 6.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.91% | -41.53% | 28.35% | 142.27% | 15.54% |
| Foreign Exchange rate Adjustments | 447.01% | -111.66% | 672.85% | 109.01% | -193.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -36.57% | 43.87% | 45.73% | 52.10% | 43.23% |